Table 1.
Immunohistochemical data
| Patients | Tumor type | OCT long-term therapy | OCT pre-/peri-OP | Sst2 IHCa | ARG |
|---|---|---|---|---|---|
| Octreotide-treated | |||||
| 1 | NET (pancreatic) | LAR 20 mg 3 wk pre-OP | 200 μg/h infusion peri-OP | Mostly internal. sst2 | +++ |
| 2 | NET (bronchial; heart-met) | LAR 20 mg 3 wk pre-OP | 200 μg/h infusion peri-OP | Mostly internal. sst2 | NT |
| 3a | NET (pancreatic) | No | 200 μg sc | Mostly internal. sst2 | +++ |
| 3b | NET (pancreatic) | No | 200 μg sc | Mostly internal. sst2 | +++ |
| 4a | NET (pancreatic) | No | 200 μg sc | Internal. = membr. sst2 | NT |
| 4b | NET (pancreatic) | No | 200 μg sc | Internal. = membr. sst2 | NT |
| 5a | NET (pancreatic; primary) | No | 200 μg sc | Internal. = membr. sst2 | +++ |
| 5b | NET (pancreatic; liver-met) | No | 200 μg sc | Internal. = membr. sst2 | +++ |
| 6 | NET (pancreatic) | No | 200 μg sc | Membr. > internal. sst2 | +++ |
| 7 | NET (pancreatic) | No | 200 μg sc | Mostly membr. sst2 | +++ |
| 8 | NET (pancreatic) | No | 200 μg sc | Mostly membr. sst2 | +++ |
| 9 | NET (pancreatic) | No | 200 μg sc | Mostly membr. sst2 | +++ |
| Untreated | |||||
| 10 | NET (bile duct) | No | No | Membr. sst2 | ++ |
| 11a | NET (pancreatic) | No | No | Membr. sst2 | +++ |
| 11b | NET (pancreatic) | No | No | Membr. sst2 | +++ |
| 12 | NET (bronchial) | No | No | Membr. sst2 | NT |
| 13 | NET (mesenteric) | No | No | Membr. sst2 | +++ |
| 14 | NET (pancreatic; liver-met) | No | No | Membr. sst2 | +++ |
| 15 | NET (pancreatic) | No | No | Membr. sst2 | +++ |
ARG, Somatostatin receptor autoradiography; IHC, immunohistochemistry; internal., internalized; membr., membranous; NET, neuroendocrine tumor; OCT, octreotide; OP, operation; met, metastasis; NT, not tested. +++ indicates high density of somatostatin receptors (>8000 dpm/mg tissue); ++ represents a density of 4567 dpm/mg tissue.
a
All three sst2 antibodies (R2-88, UMB-1, and SS-800) were tested in each case with comparable results.